AleAnna (NASDAQ:ANNA – Get Free Report) and TNF Pharmaceuticals (NASDAQ:TNFA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.
Risk & Volatility
AleAnna has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500. Comparatively, TNF Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.
Insider & Institutional Ownership
38.1% of AleAnna shares are held by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are held by institutional investors. 42.9% of AleAnna shares are held by insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AleAnna | 1 | 0 | 0 | 0 | 1.00 |
| TNF Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Valuation and Earnings
This table compares AleAnna and TNF Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AleAnna | $1.42 million | 399.43 | -$12.34 million | $0.04 | 212.75 |
| TNF Pharmaceuticals | N/A | N/A | -$23.36 million | ($231.00) | -0.01 |
AleAnna has higher revenue and earnings than TNF Pharmaceuticals. TNF Pharmaceuticals is trading at a lower price-to-earnings ratio than AleAnna, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares AleAnna and TNF Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AleAnna | -46.01% | -14.90% | -8.74% |
| TNF Pharmaceuticals | N/A | -69.21% | -33.98% |
Summary
AleAnna beats TNF Pharmaceuticals on 8 of the 10 factors compared between the two stocks.
About AleAnna
AleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy’s natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.
About TNF Pharmaceuticals
TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Receive News & Ratings for AleAnna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AleAnna and related companies with MarketBeat.com's FREE daily email newsletter.
